Karine  Flem-Karlsen

Ms. Karine Flem-Karlsen


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2018 in Trends in Cancer
Verified
Journal Article
Open access
KFKarine Flem-Karlsen
Karine Flem-Karlsen
ØFØystein Fodstad
Øystein Fodstad
Ming TanMing Tan
Ming Tan
CNCaroline Nunes-Xavier
Caroline Nunes-Xavier
B7-H3, a member of the B7 family of immunoregulatory proteins, is overexpressed in cancer and promotes tumor growth, metastasis, and drug resistance. We discuss here the involvement of B7-H3 in cancer that goes beyond its immune regulatory function, and discuss the potential of B7-H3 as a biomarker and therapeutic target.

16 March 2022 in mAbs
Verified
Journal Article
Open access
RARahmad Akbar
Rahmad Akbar
HBHabib Bashour
Habib Bashour
Puneet RawatPuneet Rawat
Puneet Rawat
PRPhilippe A. Robert
Philippe A. Robert
ESEva Smorodina
Eva Smorodina
VGVictor Greiff
Victor Greiff
Although the therapeutic efficacy and commercial success of monoclonal antibodies (mAbs) are tremendous, the design and discovery of new candidates remain a time and cost-intensive endeavor. In this regard, progress in the generation of data describing antigen binding and developability, computational methodology, and artificial intelligence may pave the way for a new era of in silico on-demand immunotherapeutics design and discovery. Here, we argue that the main necessary machine learning (ML) components for an in silico mAb sequence generator are: understanding of the rules of mAb-antigen binding, capacity to modularly combine mAb design parameters, and algorithms for unconstrained parameter-driven in silico mAb sequence synthesis. We review the current progress toward the realization of these necessary components and discuss the challenges that must be overcome to allow the on-demand ML-based discovery and design of fit-for-purpose mAb therapeutic candidates.

12 January 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
CNCaroline Nunes-Xavier
Caroline Nunes-Xavier
KFKarine Flem-Karlsen
Karine Flem-Karlsen
CTChristina Tekle
Christina Tekle
CPCathrine Pedersen
Cathrine Pedersen
TØTove Øyjord
Tove Øyjord
ØFØystein Fodstad
Øystein Fodstad
Decreased expression of B7-H3 reduces the glycolytic capacity and sensitizes breast cancer cells to AKT/mTOR inhibitors

4 July 2017 in Pigment Cell & Melanoma Research
Verified
Journal Article
Open access
PDF file
KFKarine Flem-Karlsen
Karine Flem-Karlsen
CTChristina Tekle
Christina Tekle
YAYvonne Andersson
Yvonne Andersson
KFKjersti Flatmark
Kjersti Flatmark
ØFØystein Fodstad
Øystein Fodstad
CNCaroline Nunes-Xavier
Caroline Nunes-Xavier
Summary: B7‐H3 (CD276) belongs to the B7 family of immunoregulatory proteins and has been implicated in cancer progression and metastasis. In this study, we found that metastatic melanoma cells with knockdown expression of B7‐H3 showed modest decrease in proliferation and glycolytic capacity and were more sensitive to dacarbazine (DTIC) chemotherapy and small‐molecule inhibitors targeting MAP kinase (MAPK) and AKT/mTOR pathways: vemurafenib (PLX4032; BRAF inhibitor), binimetinib (MEK‐162; MEK inhibitor), everolimus (RAD001; mTOR inhibitor), and triciribidine (API‐2; AKT inhibitor). Similar effects were observed in melanoma cells in the presence of an inhibitory B7‐H3 monoclonal antibody, while the opposite was seen in B7‐H3‐overexpressing cells. Further, combining B7‐H3 inhibition with small‐molecule inhibitors resulted in significantly increased antiproliferative effect in melanoma cells, as well as in BRAFV600E mutated cell lines derived from patient biopsies. Our findings indicate that targeting B7‐H3 may be a novel alternative to improve current therapy of metastatic melanoma.

17 July 2023 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
GMGoran Micevic
Goran Micevic
ADAndrew Daniels
Andrew Daniels
KFKarine Flem-Karlsen
Karine Flem-Karlsen
KPKoonam Park
Koonam Park
RTRonan Talty
Ronan Talty
RFRichard A. Flavell
Richard A. Flavell
Recurrence of advanced melanoma after therapy is a major risk factor for reduced survival, and treatment options are limited. Antitumor immune memory plays a critical role in preventing melanoma recurrence and memory T cells could be a potent cell-based therapy, but the identity, and functional properties of the required immune cells are incompletely understood. Here, we show that an IL-7R hi tumor-specific CD8 + population is critical for antitumor memory and can be epigenetically augmented to drive powerful antitumor immune responses. Using a model of functional antimelanoma memory, we found that high IL-7R expression selectively marks a CD8 + population in lymphoid organs that plays critical roles in maintaining tumor remission after immunotherapy or surgical resection. This population has intrinsic cytotoxic activity, lacks markers of exhaustion and has superior antitumor efficacy. IL-7Rhi cells have a functionally poised epigenetic landscape regulated by DNA methylation, which can be augmented by hypomethylating agents to confer improved survival and complete melanoma clearance in naive mice. Importantly, greater than 95% of tumor-specific T cells in draining lymph nodes after therapy express high levels of IL-7R. This overlap between IL-7R hi and antigen-specific T cells allows for enrichment of a potent functional CD8 + population without determining antigen-specificity, which we demonstrate in a melanoma model without a known antigen. We identify that IL-7R expression in human melanoma is an independent prognostic factor of improved survival. These findings advance our basic understanding of antitumor memory and suggest a cell-based therapy using high IL-7R expression to enrich for a lymph node population with superior antitumor activity that can be augmented by hypomethylating agents.

9 January 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KFKarine Flem-Karlsen
Karine Flem-Karlsen
MNMarta Nyakas
Marta Nyakas
IFInger Nina Farstad
Inger Nina Farstad
EMErin McFadden
Erin McFadden
PWPatrik Wernhoff
Patrik Wernhoff
GMGunhild Mari Mælandsmo
Gunhild Mari Mælandsmo
Receptor tyrosine kinase AXL is a one-pass transmembrane protein upregulated in cancers and associated with lower survival and therapy resistance. AXL can be cleaved by the A Disintegrin and Metalloproteinases (ADAM)10 and ADAM17, yielding a soluble version of the protein. Elevated soluble AXL (sAXL) has been reported to be associated with disease progression in hepatocellular carcinoma, renal cancer, neurofibromatosis type 1 and inflammatory diseases. In the present work, we analyzed sAXL levels in blood from melanoma patients and showed that sAXL increases with disease progression. Additionally, increased sAXL levels were found correlated with shorter two-year survival in stage IV patients treated with ipilimumab. Furthermore, we showed that sAXL levels were related to the percentage of cells expressing AXL in resected melanoma lymph node metastases. This finding was verified in vitro, where sAXL levels in the cell media corresponded to AXL expression in the cells. AXL inhibition using the small-molecular inhibitor BGB324 reduced sAXL levels, while the cellular expression was elevated through increased protein stability. Our findings signify that quantification of sAXL blood levels is a simple and easily assessable method to determine cellular AXL levels and should be further evaluated for its use as a biomarker of disease progression and treatment response.